Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Sleep disturbances in HIV-infected patients associated with depression and high risk of obstructive sleep apnea.

Gutierrez J, Tedaldi EM, Armon C, Patel V, Hart R, Buchacz K.

SAGE Open Med. 2019 Apr 8;7:2050312119842268. doi: 10.1177/2050312119842268. eCollection 2019.

2.

Disparities in Viral Suppression and Medication Adherence among Women in the USA, 2011-2016.

Geter A, Sutton MY, Armon C, Buchacz K; HIV Outpatient Study Investigators.

AIDS Behav. 2019 Apr 9. doi: 10.1007/s10461-019-02494-9. [Epub ahead of print]

PMID:
30968277
3.

Intrinsic race differences in ALS survival in a US clinic population independent of ventilation.

Armon C, Albert SM.

Neurology. 2019 Apr 23;92(17):781-783. doi: 10.1212/WNL.0000000000007357. Epub 2019 Mar 27. No abstract available.

PMID:
30918098
4.

Smoking is a cause of ALS. High LDL-cholesterol levels? Unsure.

Armon C.

Ann Neurol. 2019 Mar 18. doi: 10.1002/ana.25469. [Epub ahead of print] No abstract available.

PMID:
30883903
5.

Smoking is a cause of amyotrophic lateral sclerosis. High low-density lipoprotein cholesterol levels? Unsure.

Armon C.

Ann Neurol. 2019 Apr;85(4):465-469. doi: 10.1002/ana.25468. No abstract available.

PMID:
30875450
6.

CT-guided thrombolytic treatment of patients with wake-up strokes.

Armon C, Wainstein J, Gour A, Levite R, Bartal A, Kriboushay A, Kenan G, Khiri F, Shevtzov E, Aroesty R, Bhonkar S, Tal S, Ilgiyaev E, Blatt A, Haitov Z, Bar-Hayim S, Kimiagar I.

eNeurologicalSci. 2019 Feb 5;14:91-97. doi: 10.1016/j.ensci.2019.02.002. eCollection 2019 Mar.

7.

[TREATMENT WITH DUAL ANTIPLATELET THERAPY FOR SECONDARY PREVENTION OF STROKE - PROS AND CONS].

Sherban A, Armon C, Rapoport M.

Harefuah. 2018 Dec;157(12):773-778. Review. Hebrew.

PMID:
30582310
8.

Robotic Mediastinal Surgery in Patients with Suspected Thymic Neoplasms: First Israeli Experience.

Peer M, Azzam S, Gofman V, Kushnir M, Davidson B, Armon C.

Isr Med Assoc J. 2018 Oct;20(10):637-641.

9.

Time spent with HIV viral load above 1500 copies/ml among patients in HIV care, 2000-2014.

Mendoza MCB, Gardner L, Armon C, Rose CE, Palella FJ Jr, Novak RM, Tedaldi EM, Buchacz K; HIV Outpatient Study Investigators.

AIDS. 2018 Sep 10;32(14):2033-2042. doi: 10.1097/QAD.0000000000001921.

PMID:
29958190
10.

From Snow to Hill to ALS: An epidemiological odyssey in search of ALS causation.

Armon C.

J Neurol Sci. 2018 Aug 15;391:134-140. doi: 10.1016/j.jns.2018.05.016. Epub 2018 May 21. Review.

PMID:
29807753
11.

Risk Factors and Incidence of Syphilis in Human Immunodeficiency Virus (HIV)-Infected Persons: The HIV Outpatient Study, 1999-2015.

Novak RM, Ghanem A, Hart R, Ward D, Armon C, Buchacz K; HIV Outpatient Study Investigators .

Clin Infect Dis. 2018 Nov 13;67(11):1750-1759. doi: 10.1093/cid/ciy348.

PMID:
29688270
12.

Correction: Trends of racial and ethnic disparities in virologic suppression among women in the HIV Outpatient Study, USA, 2010-2015.

Geter A, Sutton MY, Armon C, Durham MD, Palella FJ Jr, Tedaldi E, Hart R, Buchacz K; HIV Outpatient Study Investigators.

PLoS One. 2018 Mar 12;13(3):e0194413. doi: 10.1371/journal.pone.0194413. eCollection 2018.

13.

HIV RNA Suppression during and after Pregnancy among Women in the HIV Outpatient Study, 1996 to 2015.

Patel M, Tedaldi E, Armon C, Nesheim S, Lampe M, Palella F Jr, Novak R, Sutton M, Buchacz K; HOPS Investigators.

J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325957417752259. doi: 10.1177/2325957417752259.

PMID:
29357772
14.

Disparities in HIV Viral Load Suppression by Race/ethnicity among Men who Have Sex with Men in the HIV Outpatient Study.

Buchacz K, Armon C, Tedaldi E, Palella FJ, Novak RM, Ward D, Hart R, Durham M, Brooks J.

AIDS Res Hum Retroviruses. 2018 Jan 9. doi: 10.1089/AID.2017.0162. [Epub ahead of print]

PMID:
29316797
15.

Trends of racial and ethnic disparities in virologic suppression among women in the HIV Outpatient Study, USA, 2010-2015.

Geter A, Sutton MY, Armon C, Durham MD, Palella FJ Jr, Tedaldi E, Hart R, Buchacz K; HIV Outpatient Study Investigators.

PLoS One. 2018 Jan 2;13(1):e0189973. doi: 10.1371/journal.pone.0189973. eCollection 2018. Erratum in: PLoS One. 2018 Mar 12;13(3):e0194413.

16.

The beginning of precision medicine in ALS? Treatment to fit the genes.

Armon C, Hardiman O.

Neurology. 2017 Oct 31;89(18):1850-1851. doi: 10.1212/WNL.0000000000004612. Epub 2017 Oct 4. No abstract available.

PMID:
28978653
17.

Ethics of clinical research in patients with ALS: is there a risk of exploitation?

Armon C.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):161-166. doi: 10.1080/21678421.2017.1367402. Epub 2017 Sep 4.

PMID:
28869393
18.

Incidence of Hepatitis C Virus Infection in the Human Immunodeficiency Virus Outpatient Study Cohort, 2000-2013.

Samandari T, Tedaldi E, Armon C, Hart R, Chmiel JS, Brooks JT, Buchacz K; and the HIV Outpatient Study Investigators .

Open Forum Infect Dis. 2017 Jun 10;4(2):ofx076. doi: 10.1093/ofid/ofx076. eCollection 2017 Spring.

19.

Effect of the 2013 AHA/ASA guidelines on TPA use in acute ischemic stroke at Assaf Harofeh Medical Center in Israel.

Kimiagar I, Kalmanovich-Avnery S, Gonen OM, Sacagiu Z, Shevtzov E, Levite R, Weinstein J, Bartal A, Aroesty R, Bhonkar S, Tal S, Leonov Y, Blatt A, Haitov Z, Bar-Hayim S, Armon C.

J Neurol Sci. 2016 Oct 15;369:306-309. doi: 10.1016/j.jns.2016.08.038. Epub 2016 Aug 17.

PMID:
27653914
20.

Cardiovascular Disease Risk Prediction in the HIV Outpatient Study.

Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, Hart R, Wei SC, Loustalot F, Brooks JT, Buchacz K.

Clin Infect Dis. 2016 Dec 1;63(11):1508-1516. Epub 2016 Sep 9.

21.

Stem cells in amyotrophic lateral sclerosis: Ready for prime time?

Appel SH, Armon C.

Neurology. 2016 Jul 26;87(4):348-9. doi: 10.1212/WNL.0000000000002906. Epub 2016 Jun 29. No abstract available.

PMID:
27358334
22.

CD4 cell count at initiation of ART, long-term likelihood of achieving CD4 >750 cells/mm3 and mortality risk.

Palella FJ Jr, Armon C, Chmiel JS, Brooks JT, Hart R, Lichtenstein K, Novak RM, Yangco B, Wood K, Durham M, Buchacz K; HOPS Investigators.

J Antimicrob Chemother. 2016 Sep;71(9):2654-62. doi: 10.1093/jac/dkw196. Epub 2016 Jun 20.

PMID:
27330061
23.

Comment: Inverse association for risk of ALS and risk of all cancers.

Armon C.

Neurology. 2016 Jul 19;87(3):293. doi: 10.1212/WNL.0000000000002760. Epub 2016 May 11. No abstract available.

PMID:
27170568
24.

Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine.

Weinberg A, Curtis D, Ning MF, Claypool DJ, Jalbert E, Patterson J, Frank DN, Ir D, Armon C.

Front Immunol. 2016 Apr 15;7:142. doi: 10.3389/fimmu.2016.00142. eCollection 2016.

25.

Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005-2015 update.

Armon C.

Muscle Nerve. 2016 Jun;53(6):842-9. doi: 10.1002/mus.25049. Epub 2016 Apr 8.

PMID:
26799358
26.

A Matter of Perspective: Comparison of the Characteristics of Persons with HIV Infection in the United States from the HIV Outpatient Study, Medical Monitoring Project, and National HIV Surveillance System.

Buchacz K, Frazier EL, Hall HI, Hart R, Huang P, Franklin D, Hu X, Palella FJ, Chmiel JS, Novak RM, Wood K, Yangco B, Armon C, Brooks JT, Skarbinski J.

Open AIDS J. 2015 Dec 7;9:123-33. doi: 10.2174/1874613601509010123. eCollection 2015.

27.

Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011.

Sheth AN, Ofotokun I, Buchacz K, Armon C, Chmiel JS, Hart RL, Baker R, Brooks JT, Palella FJ Jr.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):47-56. doi: 10.1097/QAI.0000000000000813.

28.

Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children.

Curtis D, Ning MF, Armon C, Li S, Weinberg A.

Vaccine. 2015 Sep 11;33(38):4790-7. doi: 10.1016/j.vaccine.2015.07.082. Epub 2015 Aug 1.

PMID:
26241950
29.

Low bone mineral density and risk of incident fracture in HIV-infected adults.

Battalora L, Buchacz K, Armon C, Overton ET, Hammer J, Patel P, Chmiel JS, Wood K, Bush TJ, Spear JR, Brooks JT, Young B; HIV Outpatient Study (HOPS) and SUN Study Investigators.

Antivir Ther. 2016;21(1):45-54. doi: 10.3851/IMP2979. Epub 2015 Jul 21.

PMID:
26194468
30.

Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.

Buchacz K, Wiegand R, Armon C, Chmiel JS, Wood K, Brooks JT, Palella FJ Jr.

HIV Clin Trials. 2015 Aug;16(4):139-46. doi: 10.1179/1528433614Z.0000000019. Epub 2015 Jul 1.

31.

Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011.

Buchacz K, Young B, Palella FJ Jr, Armon C, Brooks JT; HIV Outpatient Study (HOPS) investigators; HIV Outpatient Study HOPS investigators.

J Antimicrob Chemother. 2015 Aug;70(8):2337-46. doi: 10.1093/jac/dkv120. Epub 2015 May 15.

PMID:
25979729
32.

A blow to the head trauma--ALS hypothesis.

Armon C, Albert SM.

Neurology. 2015 Apr 28;84(17):1728-9. doi: 10.1212/WNL.0000000000001528. Epub 2015 Apr 1. No abstract available.

PMID:
25832659
33.

Factors associated with cancer incidence and with all-cause mortality after cancer diagnosis among human immunodeficiency virus-infected persons during the combination antiretroviral therapy era.

Patel P, Armon C, Chmiel JS, Brooks JT, Buchacz K, Wood K, Novak RM.

Open Forum Infect Dis. 2014 May 27;1(1):ofu012. doi: 10.1093/ofid/ofu012. eCollection 2014 Mar.

34.

Management of withdrawal delirium (delirium tremens).

Armon C.

N Engl J Med. 2015 Feb 5;372(6):580. doi: 10.1056/NEJMc1415679. No abstract available.

PMID:
25651265
35.

Seasonal influenza vaccination rates in the HIV outpatient study-United States, 1999-2013.

Durham MD, Buchacz K, Armon C, Patel P, Wood K, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

Clin Infect Dis. 2015 Mar 15;60(6):976-7. doi: 10.1093/cid/ciu979. Epub 2014 Dec 11. No abstract available.

PMID:
25501987
36.

Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).

Palella FJ Jr, Armon C, Buchacz K, Chmiel JS, Novak RM, D'Aquila RT, Brooks JT; HOPS Investigators.

J Antimicrob Chemother. 2014 Oct;69(10):2826-34. doi: 10.1093/jac/dku190. Epub 2014 Jun 16.

PMID:
24942257
37.

Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?

Yangco BG, Buchacz K, Baker R, Palella FJ, Armon C, Brooks JT; HIV Outpatient Study Investigators.

AIDS Patient Care STDS. 2014 Jun;28(6):280-3. doi: 10.1089/apc.2013.0270. Epub 2014 May 15.

38.

The underestimation of familial ALS and counseling patients with sporadic ALS.

Armon C.

Neurology. 2014 Jan 7;82(1):13-4. doi: 10.1212/01.wnl.0000438234.86588.10. Epub 2013 Dec 4. No abstract available.

PMID:
24306003
39.

Peer recommendations on how to improve clinical research, and Conference wrap-up.

Chad DA, Rowland LP, Armon C, Bedlack R, Durham H, Factor-Litvak P, Heiman-Patterson T, Heitzman D, Lacomis D, Ludolph A, Maragakis N, Miller R, Pattee G, Shoesmith C, Sorenson E, Turner MR.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:67-73. doi: 10.3109/21678421.2013.778605.

PMID:
23678882
40.

ALS Untangled No. 20: the Deanna protocol.

ALSUntangled Group, Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, Mozaffar T, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Pioro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. doi: 10.3109/21678421.2013.788405. Epub 2013 May 2. Review. No abstract available.

PMID:
23638638
41.

Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.

Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, Brooks JT; , and the HOPS Investigators.

J Gen Intern Med. 2013 Oct;28(10):1302-10. doi: 10.1007/s11606-013-2449-6. Epub 2013 Apr 20.

42.

Association between opioid use and health care utilization as measured by emergency room visits and hospitalizations among persons living with HIV.

Koeppe J, Lyda K, Armon C.

Clin J Pain. 2013 Nov;29(11):957-61. doi: 10.1097/AJP.0b013e31827c7b05.

PMID:
23370078
43.

Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients.

Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, Wood K, Holmberg SD, Brooks JT; HOPS Investigators.

Prev Chronic Dis. 2013;10:E10. doi: 10.5888/pcd10.120083.

44.

A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.

Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R.

Antivir Ther. 2012;17(7):1301-9. doi: 10.3851/IMP2350. Epub 2012 Sep 5.

PMID:
22948290
45.

Is head trauma a risk factor for amyotrophic lateral sclerosis? An evidence based review.

Armon C, Nelson LM.

Amyotroph Lateral Scler. 2012 Jun;13(4):351-6. doi: 10.3109/17482968.2012.660954. Epub 2012 Mar 16. Review.

PMID:
22424129
46.

Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials*.

Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL; American Association of Neuromuscular and Electrodiagnostic Medicine.

J Clin Neurophysiol. 2012 Feb;29(1):101-8. doi: 10.1097/WNP.0b013e31824a397e.

PMID:
22353994
47.

Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society.

Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; American Clinical Neurophysiology Society.

Neurology. 2012 Feb 21;78(8):585-9. doi: 10.1212/WNL.0b013e318247fa0e.

PMID:
22351796
48.

CD4 Cell Counts at HIV Diagnosis among HIV Outpatient Study Participants, 2000-2009.

Buchacz K, Armon C, Palella FJ, Baker RK, Tedaldi E, Durham MD, Brooks JT.

AIDS Res Treat. 2012;2012:869841. doi: 10.1155/2012/869841. Epub 2011 Sep 20.

49.

The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population.

Armon C, Lichtenstein K.

Qual Life Res. 2012 Aug;21(6):993-1003. doi: 10.1007/s11136-011-0017-2. Epub 2011 Sep 22.

PMID:
21938643
50.

Variables associated with decreasing pain among persons living with human immunodeficiency virus: a longitudinal follow-up study.

Koeppe J, Lyda K, Johnson S, Armon C.

Clin J Pain. 2012 Jan;28(1):32-8. doi: 10.1097/AJP.0b013e318220199d.

PMID:
21642847

Supplemental Content

Support Center